MELISSA GINGERICH: Open Payments
NPI 1073262903 · CLAREMORE, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,250 in 114 payments from 21 companies in 2025. Trend: 2023 $1,536 · 2024 $1,996 · 2025 $2,250
Food & beverage: $2,250
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $390 |
| ABBVIE INC. | 22 | $365 |
| PFIZER INC. | 15 | $276 |
| Amgen Inc. | 10 | $219 |
| Lilly USA, LLC | 9 | $134 |
| Janssen Pharmaceuticals, Inc | 5 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $83 |
| Astellas Pharma US Inc | 4 | $82 |
| Novo Nordisk Inc | 4 | $71 |
| Exact Sciences Corporation | 3 | $65 |
Products named: FARXIGA, ELIQUIS, VRAYLAR, UBRELVY, OTEZLA, AIRSUPRA, REXULTI, SPRAVATO.
Industry payments across OK — which companies pay providers there.
